Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Zangerle

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
AIDS (London, England)|February 24, 2001
Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997E L Op de Coul, M Prins, M Cornelissen, et al.
HIV Medicine|October 7, 2017
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensA Cozzi-Lepri, R Zangerle, L Machala, et al.
HIV Medicine|September 15, 2016
Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patientsV Bouteloup, C Sabin, A Mocroft, et al.
HIV Medicine|June 27, 2020
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatmentA Mocroft, B Neesgard, R Zangerle, et al.
HIV Medicine|September 15, 2016
Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in EuropeA Judd, R Lodwick, A Noguera-Julian, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2013
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy eraA Mocroft, H J Furrer, J M Miro, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
AIDS (London, England)|February 24, 2001
Using phylogenetic analysis to trace HIV-1 migration among western European injecting drug users seroconverting from 1984 to 1997E L Op de Coul, M Prins, M Cornelissen, et al.
HIV Medicine|October 7, 2017
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimensA Cozzi-Lepri, R Zangerle, L Machala, et al.
HIV Medicine|September 15, 2016
Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patientsV Bouteloup, C Sabin, A Mocroft, et al.
HIV Medicine|June 27, 2020
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatmentA Mocroft, B Neesgard, R Zangerle, et al.
HIV Medicine|September 15, 2016
Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in EuropeA Judd, R Lodwick, A Noguera-Julian, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 8, 2013
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy eraA Mocroft, H J Furrer, J M Miro, et al.
Pageof 8